Sigachi Industries Limited has informed the Exchange about Investor Presentation
To
Date: May 30, 2025
The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 (BSE Scrip Code: 543389)
The Manager National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai- 400051 (NSE Symbol: SIGACHI)
Dear Sir/Madam,
Sub: Investor Presentation for Q4 FY 2024-25
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015, and with reference to the subject cited, please find enclosed the Investor Presentation for Q4 FY 2024-25. The same is also uploaded on the website of the Company www.sigachi.com
Request you to kindly take the same on record.
Thanking You,
Yours faithfully For Sigachi Industries Limited
Vivek Kumar Company Secretary & Compliance Officer
SIGACHI INDUSTRIES LTD
Q 4 F Y 25 Investor Pres e nta tio n
3 0 t h M a y ’ 2 0 2 5
1
Safe Harbour
No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Sigachi Industries Limited (hereinafter referred to as “Sigachi” or “Company”), which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from. This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.
2
Agenda
01. Operational & Financial Highlights
03. Competitive Edge
02. Business Overview
04. Annexure
3
About Sigachi
PURPOSE
EXPERIENCE EXCELLENCE WITH OVER
WE ARE ONE OF THE
SIGACHI VALUES
To become the leading player in offering customized solutions, with the objective of creating a Healthier, Happier and Joyful World.
Year’s OF INDUSTRY LEADERSHIP
MISSION
GLOBAL REACH
PRODUCT RANGE
To be the best managed, fastest growing company, employing Innovation to deliver customized affordable solutions to the Pharma, Food, Nutrition and the Healthcare industry.
Sigachi believes in every stakeholder i.e. Customers, Suppliers, Employees, Shareholders and the Planet Earth to “Experience Excellence”.
PRODUCT AND SERVICE OFFERINGS
Purpose-Driven Customer Obsession
Unwavering Bias for Action
Leadership Through Extreme Ownership
Strength in Growth Mindset
PHARMACEUTICAL EXCIPIENTS
ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)
FILM COATINGS
POLYMER BLENDS
FOOD & NUTRITION
OPERATIONS & MANAGEMENT
Excellence as One Team
4
FY25: A Year of Transformation, Innovation, and Global Growth FY25 has been a year of transformation and growth for Sigachi Industries. We have strengthened our market leadership through strategic capacity expansions, robust financial performance, and a growing global footprint. Our commitment to R&D excellence is reflected in the upcoming API R&D facility in Hyderabad, which will drive innovation and enhance our product pipeline. Together, we are poised to achieve new milestones in FY26 and beyond.
Mr. Amit Raj Sinha MD & CEO
5
Our Core Strengths and Capabilities
500 + Customers across 65+ Countries
5 State of the art facilities, strategically located in Hyderabad, Sultanpur, Jhagadia, Dahej & Raichur
Operating at a combined capacity of 30,000 MTPA across 4 strategic locations
Offering 100+ Products alongside tailored, customer centric solutions
Delivering consistent quality and tailored solutions to meet the evolving needs of our customers.
Global Presence
Manufacturing Facilities
Production Capacity
Product Range
Strong Customer Relationship
29%
35%
28%
Our facilities are accredited with EXCiPACT, WHO-GMP, GMP, SGMP, HACCP, EDQM CEP, FSSAI, USFDA, ISO 9001:2015 and more.
1500+ global employee base
5 Years Revenue CAGR
5 Years EBITDA CAGR
5 Years PAT CAGR
Quality Compliance
Employees
6
Core Business More Than Doubled in 5 Years
MCC Revenue Grew 2.1x
Revenue (Rs. Mn)
MCC Revenue CAGR : 26.47% (FY20-FY25)
11,446
12,793
12,655
14,740
19,100
4,093
9,159
1,265
FY20
1,773
FY21
2,266
2,603
3,015
FY22
FY23
FY24
FY25
Revenue (Rs. Mn)
Volume (MTPA)
7
Operational and Financial Highlights
Business Overview
Competitive Edge Driving Profitability and Financial Stability
Annexure
8
Business Update- Q4 & FY25
Consolidating critical API developments and analytical efforts under one roof
Other Updates
Its Sultanpur, Hyderabad facility was approved by Intertek on behalf of GAIN
o Strategic entry into
coatings market to harness growth potential
New API R&D facility in Hyderabad to be operational by Q1 FY26
Focused on enhancing R&D and cost-effective manufacturing
Achieved GAIN (Global Alliance for Improved Nutrition) Audit Certification
Reinforces Sigachi’s commitment to quality and leadership in food and nutrition
o Expertise in
pharmaceutical formulations drives innovation.
o State-of-the-art facilities ensure superior product quality
6%2%
8%
FY25 – Revenue Mix
84%
MCC
O&M API
Allied Trade
Total Income (Rs. Mn)
Total Income Growth
4,106
FY24
23.89% YOY
5,087
FY25
9
ESG Performance FY25
Progressing Towards A BETTER TOMORROW, Operating Responsibly Growing Sustainably
Environment
Social
•
• Maintaining 98% ESG compliance of Targeted Suppliers in our supply chain Sustainable Processing of 100% of our input packaging material double Conducted to assessment environmental risks and opportunities
materiality key
identify
•
Social Employee Wellbeing • Great Place To Work® re-certification • • • Corporate Social Responsibility • Over 12,600+
338 new hires 9.4% gender diversity 0 fatalities
lives touched
in
through CSR initiatives
Corporate Governance
Governance
•
•
100% Average Board meeting attendance 50% Independent board directors
Shareholders: Uninterrupted Value creation by Multiple diverse Business Verticals in the conglomerate
Customers: Increased trust on brands and Products owing to respected customer-first global avatar
India
People : Unlocks intrinsic motivation to explore various opportunities inside the system
Community: Larger expenditure towards CSR & Significant increase in ESG focus to achieve sustainability goals
10
Q4FY25 Financial Highlights
Revenue from Operational Income (Rs. Mn)
Rs. 1,282 Mn
23.15% YOY
EBITDA (Rs. Mn)
Rs. 285 Mn
74.84 % YOY
88%
75%
Revenue Contribution %
PAT (Rs. Mn)
Margins
Rs. 162 Mn
7.28 % YOY
EBITDA : 22.31%
666 bps (YoY)
PAT : 12.63% (197) bps (YoY)
9%
9%
12%
2%
4%
1%
MCC
Operations and Management
API
Allied Trades
Q4FY24
Q4FY25
11
FY25 Financial Highlights
Revenue from Income* (Rs. Mn)
Rs. 5,003 Mn
25.42 % YOY
EBITDA* (Rs. Mn)
Rs. 1,120 Mn
46.21 % YOY
84%
76%
Revenue Contribution %
PAT (Rs. Mn)
Margins
Rs. 705Mn
23.25 % YOY
* Includes Revenue from PLI
EBITDA : 22.38%
318 bps (YoY)
PAT : 14.09% (25) bps (YoY)
9%
8%
12%
6%
3%
2%
MCC
Operations and Management
API
Allied Trades
FY24
FY25
12
Q4 & FY25 Story in Charts
Revenue from Operations (Rs. Mn)
EBITDA(Rs. Mn) & EBITDA Margin
PAT (Rs. Mn) & PAT Margin
5 2 Y F 4 Q
5 2 Y F
1,041
Q4FY24
3,989
FY24
1,282
Q4FY25
163
Q4FY24
285
152
162
Q4FY25
Q4FY24
Q4FY25
5,003
766
1,120
FY25
FY24
FY25
572
FY24
705
FY25
13
Uptick in MCC Quantity
Volume of Microcrystalline Cellulose (In MT)
46.07%
29.57%
5,400
5,580
3,820
19,100
14,740
Q4FY24
Q3FY25
Q4FY25
FY24
FY25
14
Revenue Growth in MCC (Rs. Mn)
35.75%
Key Drivers
Revenue in MCC Experienced Robust Growth
4,093
Attributed to Increased Demand and Ramp up in Capacity Utilization
3,015
FY24
FY25
Average Price of MCC for the FY25 was at Rs 214.26 per kg
15
Revenue Growth in O&M (Rs. Mn)
17.66%
Key Drivers
• Revenue Growth is mainly attributable to increase in customers.
351
413
FY24
FY25
16
Strategic Priorities and Way Forward
MCC
Market Expansion
API
CCS
O&M
o Enhanced
Utilization: Striving for 80% Capacity Utilization added of Capacity by FY26
o Geographic Expansion: Deepen with market existing customers and expand into new regions
penetration
o Broaden Market Footprint: Target B2B growth in human nutrition and expand excipient exports across 60 countries
o Committed to R&D Excellence: Establishing a new R&D center in Hyderabad to unify API developments and analytics, with operations for Q1 FY26.
set
o
Strategic Capacity Expansion: growing market To meet future demand and support scalability. This will enhance our manufacturing capabilities, enabling us to increase output, improve operational efficiency
o Commercializing CCS : Aim to commercialize CCS within 18 months.
o Advanced O&M Services: Focus chemicals, specialty on petrochemicals, water treatment, and pharma plants, 4.0 leveraging enhanced technologies efficiency and compliance
industry for
17
Income Statement Q4 & FY25
Particulars (Rs. Mn)
Revenue from Operational Income*
Total Expenses
EBITDA
EBITDA Margin
Depreciation and Amortization
Finance Cost
Other Income
PBT
PBT Margin
Tax Expense
PAT
PAT Margin
Other Comprehensive Income
Total Comprehensive Incomes
Basic EPS (Rs Per Share)
Diluted EPS (Rs Per Share)
Q4FY25
1,282
997
285
Q4FY24
YoY
Q3FY25
QoQ
1,041
878
163
23.15%
13.55%
74.84%
1,394
1,062
(8.03)%
(6.12)%
332
(14.15)%
FY25
5,003
3,883
1,120
FY24
3,989
3,223
766
YoY
25.42%
20.48%
46.21%
22.31%
15.65%
666 Bps
23.81%
(150) Bps
22.38%
19.20%
318 Bps
47
33
22
227
35
29
72
171
32.75%
47
38
20
267
(14.98)%
158
124
85
923
108
78
117
697
17.70%
16.52%
118 Bps
19.15%
(145) Bps
18.44%
17.47%
65
162
20
151
225%
7.28%
62
205
4.83%
(20.97)%
219
705
125
572
32.42%
97 Bps
75.2%
23.25%
12.63%
14.60%
(197) Bps
14.70%
(207) Bps
14.09%
14.34%
(25) Bps
-4
158
0.36
0.39
2
153
0.48
0.41
3.27%
(25.00)%
(4.87)%
1
206
0.65
0.52
(44.61)%
(25.00)%
-1
703
2.06
2.06
-
572
1.81
1.54
22.90%
13.81%
33.77%
All numbers are on Consolidated Basis ; FY25- Includes Rs.121 Mn as PLI Income.
18
Operational and Financial Highlights
Business Overview
Competitive Edge Driving Profitability and Financial Stability
Annexure
19
Sigachi Industries – Distinct Value Proposition
Sigachi Industries Ltd: Leading Manufacturer of Pre-Formulation Excipients
Presence in the Pharmaceutical Ecosystem
Competitive Edge
Largest MCC Manufacturing companies in India
Growth in API product portfolio and CEP Filings in pipeline
20
Present Across the Pharma Ecosystem
Pharma & Formulations
Pharma & API Intermediates
Pharma Excipients
Film Coatings, F&N Coatings
Formulators
Doctors
End Customers
Moving Up the Value chain by Introducing Value Added and Margin Accretive Products in the Product Basket
21
One of the Largest Manufacturers of MCC in the World
Maximizing Capacity: Efficient Utilization (FY25)
The capacity (7,200 MTPA) added in Q4FY24 resulted in an increase to total capacity of 21,700 MTPA
85.03%
8,400
7,143
6,900
5,912
85.68%
98.93%
6,400
Dahej
Jhagadia
Hyderabad
Installed Capacity (MTPA)
Production (MTPA)
Capacity Utilization%
Leading MCC Manufacturer in India
Operating at a combined capacity of 21,700 MTPA across 3 strategic locations
Expanded capacity has achieved 68% utilization in FY25
Expanded Capacities are expected to be fully utilized by FY 27.
22
Robust Growth in O&M Business
Revenue More than Tripled
O&M Revenue (Rs. Mn)
413
351
265
110
122
134
FY20
FY21
FY22
FY23
FY24
FY25
Trusted Partners o Gujarat Alkalies o Aditya Birla Group o ONGC Petro Additions o Lords Chloro Alkali Limited o Zinc Fertilizers Pvt Ltd o Gujarat Nalco Alkalis & Chemicals Pvt Ltd.
Asset Light Model o Zero Capex Requirement o Contracts Win to Boost RoE and
RoCE
23
Research & Product Excellence
Advanced Manufacturing Facilities across 5 Strategic Locations
Hyderabad Plant
Dahej SEZ Plant
Quality Assurance through Cutting-edge Facilities, Expert R&D, Accreditation and USFDA approved facility for Manufacturing Critical & Advanced intermediates. DMF for Coatings
Manufacturing Units o Five manufacturing facilities (Telangana, Gujarat, Karnataka) including SEZ and dedicated nutritional premix facility.
Research & Development
o Two state-of-the-art R&D labs located in Dahej and focusing on Jhagadia performance-oriented approaches and in-house technologies
Jhagadia Plant
Trimax Biosciences API Plant
Sultanpur Plant
Expansion Plans
o Expanding Dahej, Jhagadia Capacities for MCC
o Setting up New Dahej
Unit for CCS
Accredited Laboratory
at
o Laboratory
Dahej accredited by Department of Science and Industrial Research (DSIR).
24
Ongoing Commitment to R&D Investment
Trademarks
Patent Filed
46
7
Investment in Intellectual Properties : R&D (In Rs. Mn)
44.12
FY22
37.41
FY23
49.6
FY24
CEP
4
66.04
FY25
25
Quality Assurance: Certifications & Accreditation
Ensures quality control and assurance in all manufacturing units, with various certifications for processes and raw materials
26
Operational and Financial Highlights
Business Overview
Competitive Edge Driving Profitability and Financial Stability
Annexure
27
Achieving 3x Growth in Revenue and PAT Over a Period of 5 Years
Revenue (Rs. Mn)
EBITDA (Rs. Mn)
PAT (Rs. Mn)
PAT
20.1%
21.2%
19.4%
19.2%
22.4%
17.8%
16.0%
15.7%
5,088
4,106
14.6%
1,120
3,087
2,529
1,439
1,960
248
388
530
587
767
303
203
14.4%
14.3%
703
400
435
14.1%
572
FY20
FY21
FY22
FY23
FY24
FY25
FY20
FY21
FY22
FY23
FY24
FY25
FY20
FY21
FY22
FY23
FY24
FY25
Revenue (Rs. Mn)
EBITDA (Rs.Mn)
EBITDA Margin
PAT (Rs. Mn)
PAT Margin
Margin
EBITDA
PAT
5 Years CAGR (FY20-25)
5 Year Average Margin (FY20-25)
35%
28%
20.5%
14.9%
Nos. are consolidated basis
28
Low Debt: Maximizing Financial Stability
Gross Block (Rs. Mn)
Net Debt to Equity and Interest Coverage Ratio
3,456
2,157
416.5
FY20
503.3
FY21
1,151
682.5
FY22
FY23
FY24
FY25
45.31
0.28
FY20
10.56
31.04
0.02
FY21
13.68
0.03
0.13
FY22
FY23
FY24
0.04
FY25
5.56
-0.15
9.82
Net Debt to Equity
Interest Coverage Ratio
29
Cash Flow
To Drive Future Growth
Cash Flows from Operation (Rs. Mn)
Capex (Rs. Mn)
296
290
269
121
129
59
FY20
FY21
FY22
FY23
FY24
FY25
1,007
852
433
FY23
FY24
FY25
93
FY21
243
FY22
30
Operational and Financial Highlights
Business Overview
Competitive Edge Driving Profitability and Financial Stability
Annexure
31
Historical Income Statement
Particulars (Rs. Mn)
Revenue from Operational Income*
Total Expenses
EBITDA
EBITDA Margin
Depreciation and Amortisation
Finance costs
Other Income
PBT
PBT Margin
Tax Expense
PAT
PAT Margin
Other Comprehensive Income
Total Comprehensive Income
Basic EPS
Diluted EPS
FY21
1,928
1,540
388
FY22
2,503
1,972
531
20.12%
21.21%
23
13
33
385
20.0%
82
303
15.72%
1
304
1.31
1.31
29
12
26
516
20.6%
116
400
15.98%
-6
394
1.54
1.54
FY23
3,020
2,433
587
19.43%
66
43
67
545
18.0%
109
436
14.43%
1
437
1.41
1.41
FY24
3,989
3,223
766
19.20%
108
78
117
697
17.47%
125
572
14.34%
-
572
1.81
1.54
FY25
5,003
3,883
1,120
22.38%
158
124
85
923
18.44%
219
705
14.09%
-1
703
2.06
2.06
All numbers are on Consolidated Basis ; *FY25- Includes Rs.121 Mn as PLI Income
32
Historical Balance Sheet
Particulars (Rs. Mn)
NON-CURRENT ASSETS
a) Property, plant and equipment
b) Capital work-in-progress
c) Intangible assets
d) Goodwill
e) Right of Use Assets
f) Financial assets
i) Investments
ii) Other Financial Assets
g) Other non-current assets
CURRENT ASSETS
a) Financial Assets
i) Trade Receivables
ii) Cash and cash equivalents
iii) Bank balances other than above
iv) Other financial assets
b) Other current assets
c) Inventories
TOTAL ASSETS
All numbers are on Consolidated Basis
FY21
463
376
37
3
-
-
2
18
27
871
358
159
21
100
21
212
FY22
1,069
527
97
7
-
-
2
351
85
1,799
601
291
403
128
71
305
FY23
1,964
960
349
7
-
257
2
225
164
1,774
802
137
190
69
110
466
FY24
3,809
1,711
966
14
547
277
3
199
92
3,133
1,500
174
396
163
192
707
FY25
4,519
2,876
86
13
547
268
2
329
398
3,943
1,837
173
547
267
176
943
1,334
2,868
3,738
6,942
8,462
33
Historical Balance Sheet
Particulars (Rs. Mn)
EQUITY
Equity Share Capital
Other Equity
Equity attributable to the owners of the company
Minority Interest
NON-CURRENT LIABILITIES
a) Financial Liabilities
i) Borrowings
ii) Lease Liability
b) Provisions
c) Deferred tax liabilities (net)
CURRENT LIABILITIES
a) Financial Liabilities
i) Borrowings
ii) Lease Liabilities
iii) Trade Payables
iv) Other financial liabilities
b) Other current liabilities
c) Current tax liabilities (Net)
TOTAL LIABILITIES
TOTAL EQUITY AND LIABILITIES
All numbers are on Consolidated Basis
FY21
942
77
865
942
-
70
19
-
8
43
322
183
-
80
7
43
9
392
1,334
FY22
2,277
307
1,970
2,277
-
76
12
-
9
55
515
332
-
106
6
59
12
591
2,868
FY23
2,683
307
2,376
2,683
-
308
10
231
15
52
747
395
41
208
9
94
-
1,055
3,738
FY24
4,410
328
3,968
4,296
114
653
266
205
18
164
1,878
924
36
479
80
335
24
2,531
6,942
FY25
6,131
382
5,626
6,008
122
480
-
216
28
236
1,852
1,181
25
357
1
261
27
2,332
8,462
34
Key Milestones
1989 Incorporated as ‘Sigachi Chloro- Chemicals Private Limited
2000 o Launched premium-grade
MCC production
o Installed advanced spray drier
and multi-fuel furnace
o Capacity boosted from 720 to
1080 MTPA
2010
2014
Commenced the commercial production of MCC at manufacturing unit situated at Jhagadia
Merger of Sigachi Cellulose Private Limited and Sigachi Plasticizers Private Limited with the company
2023 Expanded Capacity to 21,000 MTPA, the Largest MCC Manufacturing
Company in India
2024 Sigachi MENA FZCO, a wholly owned subsidiary, has announced the formation of joint ventures, Sigachi Arabia and Sigachi Global.
1989
1998
2000
2009
2010
2012
2014
2021
2023
2023
2024
2025
1998
Commenced its export operations by exporting its product
2009 Setting up of 100 % export oriented unit (“EOU”) for manufacturing MCC in the SEZ at Dahej, Gujarat
2012
Commenced the Commercial production of MCC at the manufacturing unit situated at Dahej
2021 Got listed on NSE & BSE on Nov 15, 2021
2023 Acquired Trimax Biosciences Pvt Ltd to expand into API product offerings
2025
Achieved GAIN (Global Alliance for Improved Nutrition) Audit Certification
Sigachi MENA FZCO, a wholly owned subsidiary, has formed a joint venture with Saudi National Projects Investment (SNP) to enter the growing Saudi Arabian market.
36
Strong Leadership
Distinct, high performing businesses aligned with business drivers and market requirements
Rabindra Prasad Sinha
Whole Time-Director & Chairman
Chidambarnathan Shanmuganathan
Whole Time-Director & Vice Chairman
Amit Raj Sinha
Managing Director & CEO
Subbarami Reddy Oruganti
Chief Financial Officer
Bhavani Chidambaranathan
President, Sigachi US, Inc.
Lijo Chacko
CEO Sigachi MEA
36
THANK YOU!
SIGACHI INDUSTRIES LTD
Corporate Office: Plot No. G 57/2, Survey no.70 & 174, Sultanpur Village, Patancheru Mandal, Hyderabad 502319, Sanga Reddy District, Telangana, India. Landline +918455242055/56/57
Registered office: 2nd floor, Kalyans Tulsiram Chambers, Madinaguda, Hyderabad 500049, Telangana, India. Landline +9140 40114874 /75/76
GO INDIA ADVISORS – IR FIRM
Ms. Priya Sen
Ms. Sana Kapoor
Ms. Sheetal Khanduja
priya@goindiaadvisors.com
sana@goindiaadvisors.com
M : +91 8334841047
M:+91 8146550469
sheetal@goindiaadvisors.com
M: +91 9769364166
37